1Y Close · As of Aug 26, 2026
AbClon operates in the Pharmaceuticals sector.
Legal name: AbClon Inc.
In fiscal year 2025, AbClon (174900) reported revenue of 4.7 billion KRW, up 101.5% from 2.3 billion KRW a year earlier.
Operating profit was -17.6 billion KRW and net income was -17.9 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 567.6 billion KRW, with a P/B of 9.39.
These figures can be verified in the DART filing (receipt no. 20260313000798).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 4.7B | -17.6B | -17.9B |
| 2024 | 2.3B | -15.6B | -16.3B |
| 2023 | 2.9B | -11.6B | -12.9B |
Recent Filings
Semi-Annual Report (2026.06)
Officer/Major Shareholder Ownership Report
Sales/Supply Contract
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-07 | Officer/Major Shareholder Ownership Report |
| 2026-08-04 | Sales/Supply Contract |